ArticlePloS one2018
Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis.Hormone research in paediatrics · 2024Pooled it
- BMI-SDS Changes During GnRHa Therapy in 150 Girls with Idiopathic Central Precocious Puberty: Follow-up Through Final HeightJournal of clinical research in pediatric endocrinology · 2026Article
- Analysis of pubertal height gain in post-menarche girls.Medicine · 2026Article
- Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis.Frontiers in pediatrics · 2026Article
- Final Adult Height in Girls Treated with GnRH Analogues for Precocious Puberty Around Age Eight.Children (Basel, Switzerland) · 2025Article
- Long-Term Efficacy and Safety of Leuprorelin Treatment in Children with Central Precocious Puberty: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2025Review
- Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty.Annals of pediatric endocrinology & metabolism · 2025Article
- Does age at menarche influence final height in female adolescents?Bioinformation · 2025Article
- Article
- Commentary on "Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty".Annals of pediatric endocrinology & metabolism · 2023Article
- Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty.Scientific reports · 2023Article
- Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.Frontiers in endocrinology · 2023Article
- Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.Frontiers in pediatrics · 2022Review
- Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty.Annals of pediatric endocrinology & metabolism · 2021Article
- Commentary on "Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty".Annals of pediatric endocrinology & metabolism · 2021Article
- Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty.Annals of pediatric endocrinology & metabolism · 2021Article
- Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty.Annals of pediatric endocrinology & metabolism · 2020Article
- The Therapeutic Effect of Shugan Xiehuo Formula in the Female Rat Model with Central Precocious Puberty.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Treatment of Central Precocious Puberty.Journal of the Endocrine Society · 2019Review
- Comparison of two different GnRH analogs' impact on final height in girls with early puberty: Triptorelin acetateActa endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for central precocious puberty (CPP) and have been widely used for several decades. We determined the effect of GnRHa treatment on the auxological outcomes of girls with idiopathic CPP.
methodsThis study included 84 girls treated monthly with depot leuprolide acetate who had reached adult height. We compared their final adult height (FAH) with their initial predicted adult height (PAH). We performed a multivariate analysis of the factors associated with FAH on all girls diagnosed with CPP.
resultsWe performed the final evaluations at a mean age of 14.1 ± 0.8 years after a mean treatment duration of 2.98 ± 0.73 years (ranging from 1.5-4.8 years). Menarche had occurred at 12.6 ± 0.6 years of age, which was 16.5 ± 6.1 months after discontinuation of GnRHa therapy. Mean FAH was 160.1 ± 5.0 cm, which was significantly higher than the initial PAH (156.1 ± 5.7 cm; P < 0.001). To investigate whether growth outcomes were influenced by the age at initial treatment, we divided all patients into two groups, those treated between 6 and 8 years (n = 23) and those treated after 8 years (n = 61); no significant differences were observed in FAH between the two groups. FAH was significantly and positively correlated with the height standard deviation score (SDS) at the end of treatment and with the target height, whereas the difference between bone age and chronological age at the start and end of treatment was negatively correlated with FAH.
conclusionFAH was significantly higher than the initial PAH in girls with CPP who were treated with GnRHa. Also, GnRHa treatment was still effective even after 8 years of age in girls with CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.